Filing Flows › Pulmonx (LUNG) › Q2 2026
Pulmonx (LUNG) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 4, 2026
Pulmonx (LUNG) reported revenue of $22.8M for the second quarter 2026 (Q2 2026), -5% from a year earlier and +11% from the quarter before. Operating margin was -39.8%, net loss $10.1M (44.3% of revenue).
Pulmonx, Q2 2026: revenue $22.8M (-5% year over year), operating margin -39.8%, net loss $10.1M, operating cash flow −$5.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $22.8M | +11% | -5% |
| Operating profit | −$9.1M | — | — |
| Net earnings | −$10.1M | — | — |
| Operating cash flow | −$5.2M | — | — |
What changed
Revenue was $22.8M in Q2 2026, down 5% year over year and up 11% from the previous quarter.
Gross margin was 78.0%, up 5.9 points from Q2 2025. Operating costs exceeded revenue by $9.1M, an operating margin of -39.8%. Operating expenses fell 16% while revenue fell 5%. The quarter ended with a net loss of $10.1M, narrower than the previous quarter's $13.7M loss.
Operating cash flow was −$5.2M. Non-cash charges added back $200K of depreciation and $3.7M of share-based compensation. Working capital and other items added $1.0M. Capital expenditures of $1K exceeded it, leaving free cash flow of −$5.2M.
Questions
What was Pulmonx's revenue in the second quarter 2026?
Pulmonx (LUNG) reported revenue of $22.8M for the second quarter 2026 (Q2 2026), -5% from a year earlier and +11% from the quarter before.
Was Pulmonx profitable in the second quarter 2026?
Operating loss was $9.1M (-39.8% of revenue) and net loss $10.1M.
Source: Pulmonx 10-Q on SEC EDGAR.